Fortrea Holdings Inc. operates as a global contract research organization (CRO), enabling the drug discovery and development continuum for the life sciences sector. The company's core offerings encompass comprehensive Phase I through IV clinical trial management, clinical pharmacology, and specialized consulting services. Fortrea partners with emerging and large biopharmaceutical, biotechnology, medical device, and diagnostic companies to manage the clinical development process and support the testing of new therapies. Originally the clinical development business of Labcorp, Fortrea was spun off as an independent, publicly traded company in 2023. With operations spanning more than 90 countries, the company utilizes data analytics and technology-driven solutions to manage trial design, patient recruitment, and regulatory compliance.
